In Vitro Activity of Ceftaroline Against Community-associated Methicillin-resistant, Vancomycin-intermediate, Vancomycin-resistant, and Daptomycin-nonsusceptible Staphylococcus Aureus Isolates

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2010 Apr 21

PMID 20404122

Citations 26

Authors

Louis Saravolatz

Joan Pawlak

Leonard Johnson

Affiliations

Soon will be listed here.

Abstract

This study assessed the in vitro activities of ceftaroline and five comparator agents against a collection of Staphylococcus aureus isolates. Ceftaroline demonstrated potent activity against community-associated methicillin-resistant S. aureus (CA-MRSA) isolates and showed bactericidal activity against vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA), heteroresistant VISA (hVISA), and daptomycin-nonsusceptible S. aureus (DNSSA) isolates. Ceftaroline may represent a bactericidal treatment option for infections caused by these pathogens.

Citing Articles

Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties.

Hoover R, Krsak M, Molina K, Shah K, Redell M Open Forum Infect Dis. 2022; 9(5):ofac090.

PMID: 35392455 PMC: 8982769. DOI: 10.1093/ofid/ofac090.

Evaluation of activity of ceftaroline on methicillin resistant blood isolates from Iran.

Abdizadeh N, Haeili M, Kafil H, Ahmadi A, Feizabadi M Iran J Microbiol. 2021; 13(4):442-448.

PMID: 34557271 PMC: 8421581. DOI: 10.18502/ijm.v13i4.6967.

The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Molina K, Morrisette T, Miller M, Huang V, Fish D Antimicrob Agents Chemother. 2020; 64(7).

PMID: 32312776 PMC: 7317994. DOI: 10.1128/AAC.00468-20.

Physical and chemical stability of ceftaroline in an elastomeric infusion device.

Al Madfai F, Zaidi S, Ming L, Wanandy T, Patel R Eur J Hosp Pharm. 2019; 25(e2):e115-e119.

PMID: 31157080 PMC: 6319413. DOI: 10.1136/ejhpharm-2017-001221.

Characterization of community-associated Staphylococcus aureus from skin and soft-tissue infections: a multicenter study in China.

Liu Y, Xu Z, Yang Z, Sun J, Ma L Emerg Microbes Infect. 2016; 5(12):e127.

PMID: 27999423 PMC: 5180372. DOI: 10.1038/emi.2016.128.

References

Sader H, Fritsche T, Jones R . Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2008; 52(3):1153-5. PMC: 2258508. DOI: 10.1128/AAC.01351-07. View

Julian K, Kosowska-Shick K, Whitener C, Roos M, Labischinski H, Rubio A . Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob Agents Chemother. 2007; 51(9):3445-8. PMC: 2043240. DOI: 10.1128/AAC.00559-07. View

Morrissey I, Ge Y, Janes R . Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents. 2009; 33(6):515-9. DOI: 10.1016/j.ijantimicag.2008.12.005. View

Vidaillac C, Leonard S, Rybak M . In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother. 2009; 53(11):4712-7. PMC: 2772315. DOI: 10.1128/AAC.00636-09. View

Vandenesch F, Naimi T, Enright M, Lina G, Nimmo G, Heffernan H . Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003; 9(8):978-84. PMC: 3020611. DOI: 10.3201/eid0908.030089. View

Wang J, Chen S, Wang J, Wu G, Chiang W, Hsueh P . Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Clin Infect Dis. 2008; 46(6):799-806. DOI: 10.1086/527389. View

Iizawa Y, Nagai J, Ishikawa T, Hashiguchi S, Nakao M, Miyake A . In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother. 2004; 10(3):146-56. DOI: 10.1007/s10156-004-0309-3. View

Brown S, Traczewski M . In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother. 2008; 53(3):1271-4. PMC: 2650548. DOI: 10.1128/AAC.01021-08. View

Hageman J, Uyeki T, Francis J, Jernigan D, Wheeler J, Bridges C . Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006; 12(6):894-9. PMC: 3373026. DOI: 10.3201/eid1206.051141. View

10.

Khosrovaneh A, Riederer K, Saeed S, Shamse Tabriz M, Shah A, Hanna M . Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2004; 38(9):1328-30. DOI: 10.1086/383036. View

11.

Ma X, Ito T, Tiensasitorn C, Jamklang M, Chongtrakool P, Boyle-Vavra S . Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 2002; 46(4):1147-52. PMC: 127097. DOI: 10.1128/AAC.46.4.1147-1152.2002. View

12.

Sader H, Fritsche T, Kaniga K, Ge Y, Jones R . Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005; 49(8):3501-12. PMC: 1196228. DOI: 10.1128/AAC.49.8.3501-3512.2005. View

13.

Jones R, Fritsche T, Ge Y, Kaniga K, Sader H . Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother. 2005; 56(6):1047-52. DOI: 10.1093/jac/dki362. View

14.

Ge Y, Biek D, Talbot G, Sahm D . In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008; 52(9):3398-407. PMC: 2533496. DOI: 10.1128/AAC.00149-08. View

15.

Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore D . In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother. 2007; 60(2):300-11. DOI: 10.1093/jac/dkm150. View

16.

Howden B, Ward P, Charles P, Korman T, Fuller A, du Cros P . Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004; 38(4):521-8. DOI: 10.1086/381202. View

17.

Charles P, Ward P, Johnson P, Howden B, Grayson M . Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004; 38(3):448-51. DOI: 10.1086/381093. View

18.

Naimi T, LeDell K, Como-Sabetti K, Borchardt S, Boxrud D, Etienne J . Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003; 290(22):2976-84. DOI: 10.1001/jama.290.22.2976. View

19.

Rybak M, Leonard S, Rossi K, Cheung C, Sader H, Sadar H . Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol. 2008; 46(9):2950-4. PMC: 2546725. DOI: 10.1128/JCM.00582-08. View

20.

Patel J, Jevitt L, Hageman J, McDonald L, Tenover F . An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis. 2006; 42(11):1652-3. DOI: 10.1086/504084. View